News

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...
"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...
Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.
The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...
Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...
[email protected] Sanofi Contacts: Media Relations Sandrine Guendoul Tel: +33 6 25 09 14 25 [email protected] Evan Berland Tel: +1 215-432-0234 [email protected] L ...
Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid ...
Sanofi’s R&D site in Vitry-Sur-Seine, near Paris. Sanofi and Regeneron said that drug candidate Itepekimab didn’t hit the main objective of a second trial.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients.
The drug, developed by Paris-based Sanofi and Tarrytown, N.Y.-based Regeneron Therapeutics, could earn approval by next March, reports Reuters.. The priority review process, which expedites the ...
Regeneron Pharmaceuticals and Sanofi will lower the price of their cholesterol drug Praluent by up to $9,500 annually for Express Scripts customers. In return, Express Scripts will grant the ...